NPM1 and acute myeloid leukemia: In line with these observations, NPM1class II AML cells exhibited reduced sensitivity to allogeneic T cell-mediated cytotoxicity ex vivo, suggesting an intrinsic mechanism by which this NPM1 subtype evades elimination by the immune system following HSCT.